amisulpride (Compound)

Synonyms:amisulpride, 71675-85-9, Solian, Aminosultopride, Deniban, Amisulprida, DAN 2163, Amisulpridum, Socian, Amisulpride [INN], Barhemsys, C17H27N3O4S, DAN-2163, 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide, 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide, APD421, Sulamid, Amisulpride (INN), 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide, Amisulpride free base, 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide, NSC-760085, 4-amino-N-((1-ethylpyrrolidin-2-yl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide, 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide, DTXSID5042613, CHEBI:64045, APD-421, 71675-85-9 (free base), 8110R61I4U, NCGC00092310-03, Amisulpiride, Benzamide, 4-amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxy-, Amisulpridum [INN-Latin], Amisulprida [INN-Spanish], DTXCID3022613, Sulpitac, 4-amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-ethylsulfonyl-2-methoxybenzamide, 4-amino-5-(ethanesulfonyl)-N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxybenzamide, SMR000449309, Deniban (TN), CAS-71675-85-9, Solian (TN), Amisulpride [INN:BAN], EINECS 275-831-7, UNII-8110R61I4U, Barhemsys (TN), 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-anisamid, Amisulpride- Bio-X, (plusmn)-amisulpride, MFCD00866691, AMISULPRIDE [MI], SL-91.1077, AMISULPRIDE [MART.], SCHEMBL34126, (+/-)-AMISULPRIDE, AMISULPRIDE [WHO-DD], GTPL963, MLS000758258, MLS000759450, MLS001424039, MLS006011769, CHEMBL243712, Amisulpride, >=98% (HPLC), BDBM81790, AMISULPRIDE [ORANGE BOOK], Amisulpride for system suitability, AMISULPRIDE [EP MONOGRAPH], BCPP000404, HMS2051K10, HMS2235M16, HMS3263D07, HMS3268L09, HMS3369K09, HMS3393K10, HMS3413G07, HMS3657E11, HMS3677G07, HMS3713N06, HMS3884A09, Pharmakon1600-01502285, BCP02089, NSC_2159, Tox21_113392, Tox21_501133, HB1879, NSC760085, STK635172, STL454297, AKOS005567252, Tox21_113392_1, AC-6820, BCP9000294, CCG-100860, CCG-220622, CCG-222437, CS-1791, DB06288, LP01133, NC00110, NSC 760085, SDCCGSBI-0633795.P001, NCGC00092310-01, NCGC00092310-02, NCGC00092310-04, NCGC00092310-06, NCGC00092310-16, NCGC00261818-01, AS-13890, BA164158, HY-14545, Amisulpride 100 microg/mL in Acetonitrile, CAS_71675-85-9, FT-0630805, S1280, SW197490-3, D07310, AB00639933-07, AB00639933-09, AB00639933_10, A837282, EN300-18166870, L000106, Q418785, SR-01000759303, SR-01000759303-5, W-104511, BRD-A60197193-001-05-4, Amisulpride, British Pharmacopoeia (BP) Reference Standard, Amisulpride, European Pharmacopoeia (EP) Reference Standard, 4-Amino-N-[(1-ethyl-2-pyrrolidinyl) methyl]-5-(ethylsulfonyl)-2-benzamide, 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-benzamide, 4-amino-5-ethanesulfonyl-n-(1-ethyl-pyrrolidin-2-ylmethyl)-2-methoxy-benzamide, 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulf onyl)-2-benzamide DAN 2163, 4-Amino-N-[(1-Ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)- 2-methoxybenzamide, 4-azanyl-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxy-benzamide, Amisulpride for system suitability, European Pharmacopoeia (EP) Reference Standard, 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-(ethylsulfonyl)-2-methoxybenzenecarboximidic acid
Pubchem:PUBCHEM:2159
Id:dadef493-fe01-5a44-a861-2f1cc31ef2e7
Description:nan

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View amisulpride's neighborhood in the knowledge graph.

Gene and Drug Landing Page Aggegrator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for amisulpride.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with amisulpride.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.